Treatment Advances

May 06, 2025

The CLIA-venetoclax regimen achieves over 90% response in AML & MDS patients, with high survival rates and low early mortality.

April 29, 2025

Learn about menin inhibitors, a new class of targeted treatments for leukemia patients with specific genetic changes.

April 25, 2025

Learn how vibecotamab targets CD123 to treat myelodysplastic syndrome, chronic myelomonocytic leukemia, and acute myeloid leukemia.

March 31, 2025

ImmunoGen’s pivekimab sunirine shows high response rates in AML, especially with azacitidine and venetoclax.

February 11, 2025

Data from ASH 2024 shows olutasidenib’s impact on AML patients with mIDH1, achieving 35% remission. Learn more about this promising treatment.

February 02, 2025

FDA approves Treosulfan (Grafapex) for AML and MDS stem cell transplant conditioning, offering a new alternative to busulfan-based regimens.

January 16, 2025

Explore breakthroughs in pediatric AML, from cardiac care to therapies, highlighted at the ASH annual conference.

December 19, 2024

Learn about cellular therapies recommended for people who have TP53-mutant acute myeloid leukemia and myelodysplastic syndromes.

November 19, 2024

Learn about revumenib, a newly FDA-approved treatment for relapsed/refractory acute leukemias with the KMT2A gene translocation.

October 24, 2024

Discover key insights into AML donor selection, HLA mismatch, and the role of donor age in improving transplant outcomes and reducing complications.